Complement Activation in Circulation and Central Nervous System after Rituximab (Anti-CD20) Treatment of B-Cell Lymphoma

References

• Reff M. E., Carner K., Chambers K. S., Chinn P. C., Leonard J. E., Raab R., Newman R. A., Hanna N., Anderson D. R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83(2)435–445
   PubMed Web of Science ®Google Scholar
• Maloney D. G., Grillo-Lopez A. J., White C. A., Bodkin D., Schilder R. J., Neidhart J. A., Janakiraman N., Foon K. A., Liles T. M., Dallaire B. K., Wey K., Royston I., Davis T., Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90(6)2188–2195
   PubMed Web of Science ®Google Scholar
• Harjunpää A., Junnikkala S., Meri S. Rituximab (anti-CD20) therapy of B cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scandinavian Journal of Immunology 2000; 51: 634–641
   PubMed Web of Science ®Google Scholar
• Maloney D., Smith B., Appelbaum F. The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood 1996; 88(637a), abstr. suppl 1
   Google Scholar
• Gorter A., Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunology Today 1999; 20(12)576–582., Immunology Today
   PubMedGoogle Scholar
• Berinstein N. L., Grillo-Lopez A. J., White C. A., Bence-Bruckler I., Maloney D., Czuczman M., Green D., Rosenberg J., McLaughlin P., Shen D. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Annals of Oncology 1998; 9(9)995–1001
   PubMed Web of Science ®Google Scholar
• Meri S., Aronen M., Leijala M. Complement activation during cardiopulmonary bypass in children. Complement Inflammation 1988; 5: 46–54
   Google Scholar
• McLaughlin P., Grillo-Lopez A. J., Link B. K., Levy R., Czuczman M. S., Williams M. E., Heyman M. R., Bence-Bruckler I., White C. A., Cabanillas F., Jain V., Ho A. D., Lister J., Wey K., Shen D., Dallaire B. K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology 1998; 16(8)2825–2833
   PubMed Web of Science ®Google Scholar
• Coiffier B., Haioun C., Ketterer N., Engert A., Tilly H., Ma D., Johnson P., Lister A., Feuring-Buske M., Radford J. A., Capdeville R., Diehl V., Reyes F. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92(6)1927–1932
   PubMed Web of Science ®Google Scholar
• Byrd J. C., Waselenko J. K., Maneatis T. J., Murphy T., Ward F. T., Monahan B. P., Sipe M. A., Donegan S., White C. A. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. Journal of Clinical Oncology 1999; 17(3)791–795
   PubMed Web of Science ®Google Scholar
• Finland Roche. 1998; 27: 11, Note for doctors
   Google Scholar
• Cheson B. D., Frame J. N., Vena D., Quashu N., Sorensen J. M. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. Journal of Clinical Oncology 1998; 16(7)2313–2320
   PubMed Web of Science ®Google Scholar
• Weisman H. F., Bartow T, Leppo M. K., Marsh H. C., Jr., Carson G. R., Concino M. F., Boyle M. P., Roux K. H., Weisfeldt M. L., Fearon D. T. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249(4965)146–151
   PubMed Web of Science ®Google Scholar
• Thomas T. C., Rollins S. A., Rother R. P., Giannoni M. A., Hartman S. L., Elliott E. A., Nye S. H., Matis L. A., Squinto S. P., Evans M. J. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Molecular Immunology 1996; 33: 17–18; 1389–1401
   Web of Science ®Google Scholar
• Nilsson B., Larsson R., Hong J., Elgue G., Ekdahl K. N., Sahu A., Lambris J. D. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 1998; 92(5)1661–1667
   PubMed Web of Science ®Google Scholar
• Sahu A., Kay B. K., Lambris J. D. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. Journal of Immunology 1996; 157(2)884–891
   PubMed Web of Science ®Google Scholar
• Brooks B., Hirsch R., Coyle P. Cellular and humoral immune responses in human cerebrospinal fluid. In Neurobiology of Cerebrospinal Fluid, J. H. Wood. Plenum, New York 1983; 300–301
   Google Scholar